Zobrazeno 1 - 6
of 6
pro vyhledávání: '"F Araujo-Rodríguez"'
Autor:
E Alfaro-Lara, María Antonia Pérez-Moreno, C Álvarez Del Vayo-Benito, A Monzon-Moreno, M Moleón-Ruiz, F Araujo-Rodríguez
Publikováno v:
Section 6: Education and Research.
Background and importance Standardisation of processes and electronic assisted prescription programmes (EAPP) are essential tools to prevent medication errors, especially relevant in vulnerable populations, such as children. Aim and objectives To sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81a0d41ad1aae6ba955a62d4682eed4b
https://doi.org/10.1136/ejhpharm-2020-eahpconf.455
https://doi.org/10.1136/ejhpharm-2020-eahpconf.455
Autor:
D Guerra Estévez, JJ Ramos-Báez, E Campos-Davila, F Araujo-Rodríguez, JC Roldán, E Marquez-Fernandez
Publikováno v:
European Journal of Hospital Pharmacy. 22:A185.2-A185
Background Our Healthcare Area is implementing Medicines Reconciliation (MedRec) supported by The European Union Network for Patient Safety and Quality of Care. In a situation of limited human resources, computerised MedRec tools could help introduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd21f6a0d0b9020bd9ea09f811205244
https://doi.org/10.1136/ejhpharm-2015-000639.446
https://doi.org/10.1136/ejhpharm-2015-000639.446
Autor:
E Campos-Davila, J Roldán-Morales, J.L. Puerto-Alonso, D Guerra Estévez, JJ Ramos-Báez, F Araujo-Rodríguez
Publikováno v:
European Journal of Hospital Pharmacy. 22:A83.2-A83
Background Our Public Healthcare Service have developed some quality indicators (QI) based on the selection of drugs that support better evidence of efficiency in areas of prescribing where more deviations were detected in the past. Purpose To descri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63336c31faeb7ec43406b7eb60f3d9e0
https://doi.org/10.1136/ejhpharm-2015-000639.199
https://doi.org/10.1136/ejhpharm-2015-000639.199
Autor:
C Beltrán-Calvo, M Galván-Banqueri, R Isabel-Gómez, F Araujo-Rodríguez, R Ubago-Pérez, T Molina-López, Vega-Coca, L Abdel-Kader Martín, MA Castillo-Muñoz
Publikováno v:
European Journal of Hospital Pharmacy. 21:A59.2-A59
Background Two anti-TNF drugs are approved to treat Crohn’s disease (CD) in Europe: infliximab and adalimumab. Purpose To compare their efficacy and safety in adult patients with moderate to severe non-fistulizing CD. Materials and methods A system
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::452315d03122e6be66eebfd4cfa49e90
https://doi.org/10.1136/ejhpharm-2013-000436.146
https://doi.org/10.1136/ejhpharm-2013-000436.146
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.